Antibody-drug conjugates (ADCs) are reshaping the future of oncology. What began as a promising targeted therapy approach has evolved into one of the most active and competitive areas in drug development. Advances in linker-payload engineering, target selection and conjugation technologies are producing increasingly sophisticated therapies with the potential to improve outcomes across a growing range of cancers.

Yet as ADC science becomes more advanced, bringing these therapies to patients is becoming increasingly complex.

Today's ADC development face a new reality: success depends not only on innovative molecular design, but also on the ability to execute smarter clinical strategies, navigate evolving regulatory expectations and manage global trial operations. In many ways, the competitive advantage has shifted from the molecule alone to how effectively sponsors develop it.

For a deeper look at the scientific, regulatory and operational trends shaping modern ADC development, read our insight brief, A New Era of ADC Development Demands a New Kind of Partner.

In today’s ADC landscape, competitive advantage is no longer defined solely by the molecule, it is increasingly determined by how effectively sponsors execute development.

A Rapidly Expanding Opportunity

The momentum behind ADCs is undeniable. More than 400 ADCs are currently in development, with approximately 200 already in clinical-stage studies. Regulatory approvals continue to accelerate, driven by advances that have improved efficacy, safety and manufacturability while expanding the therapeutic potential of these platforms.

We are also seeing innovation move beyond traditional ADC approaches. Next-generation platforms include bispecific ADCs, dual-payload constructs and novel linker technologies designed to improve target specificity and therapeutic performance. At the same time, researchers are exploring ADC applications beyond oncology, including inflammatory, autoimmune and neurological disorders.

For biotech companies, this growth creates tremendous opportunity but also intensifies competition for patients, sites and development resources.

Trial Strategy Has Become a Strategic Advantage

As ADC development becomes more complex, trial design is emerging as a critical factor in program success.

Regulators are increasingly focused on dose optimization, exposure-response relationships and biomarker-driven development strategies. Initiatives such as FDA Project FrontRunner and Project Optimus reflect a broader shift toward generating stronger clinical evidence earlier in development. Sponsors must now think beyond identifying a maximum tolerated dose and instead build comprehensive data packages that demonstrate both safety and efficacy across patient populations.

At the same time, advances in data science are helping sponsors make more informed development decisions. Artificial intelligence and predictive analytics are being used to refine target selection, optimize drug design and improve patient stratification. Emerging spatial biomarker technologies can provide deeper insights into tumor biology and antigen expression, helping identify patients most likely to benefit from treatment.

These capabilities are also improving trial execution. By combining real-world data, predictive modeling and biomarker insights, sponsors can identify high-performing sites, better forecast enrollment and strengthen patient selection strategies while helping reduce development risk and improve trial efficiency.

Global Development Requires a Broader Perspective

As ADC pipelines expand, sponsors are increasingly looking beyond traditional research hubs to accelerate enrollment and access diverse patient populations.

Asia-Pacific has become a major center for ADC innovation and clinical development, while regions such as Latin America and the Middle East are attracting growing interest from sponsors seeking additional patient access and operational flexibility.

However, expanding globally introduces challenges ranging from regulatory variation and import-export requirements to differences in site infrastructure and clinical experience. Success requires local expertise, established site networks and a development strategy that balances speed, quality and consistency across regions.

Innovation Must Be Matched by Operational Excellence

ADC trials bring unique operational demands. Cytotoxic payloads require specialized handling, infusion protocols and rigorous safety monitoring. Manufacturing and supply chains are often highly complex, and many programs depend on carefully managed cold-chain logistics to maintain product integrity across global sites.

Even the most promising ADC can face delays if these operational realities are not addressed early and effectively.

The most valuable ADC development partner is not simply one who understands the science, but one who can help transform scientific promise into clinical reality.

Looking Ahead

The future of ADC development belongs to sponsors that can connect scientific innovation with disciplined execution. Breakthrough molecules remain essential, but they are no longer enough on their own.

Biotechs that integrate smart trial design, regulatory foresight, data-driven decision-making and global operational expertise will be better positioned to accelerate development and deliver therapies to patients faster. To explore these trends and practical development considerations in greater detail, download our insight brief, A New Era of ADC Development Demands a New Kind of Partner.

As the ADC landscape continues to evolve, the strongest development programs will be those built not only on scientific promise, but on the ability to execute that promise successfully.

At IQVIA Biotech, we partner with biotech and emerging biopharma sponsors to design and deliver clinical programs aligned to this new reality, helping bring the right therapies to the right patients, at the right time, and at the scale required to make an impact.

Learn how IQVIA Biotech can support your oncology drug development journey from strategy through execution.